Jane A. Gross Purchases 3,750 Shares of Atyr PHARMA INC (NASDAQ:ATYR) Stock

Atyr PHARMA INC (NASDAQ:ATYR) Director Jane A. Gross bought 3,750 shares of Atyr PHARMA stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average price of $4.00 per share, with a total value of $15,000.00. Following the completion of the transaction, the director now owns 9,750 shares of the company’s stock, valued at $39,000. This represents a 62.50 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Atyr PHARMA Price Performance

ATYR opened at $3.87 on Wednesday. The stock has a 50-day moving average price of $3.65 and a 200-day moving average price of $3.11. Atyr PHARMA INC has a 12-month low of $1.42 and a 12-month high of $4.66. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $324.86 million, a P/E ratio of -4.12 and a beta of 0.98.

Atyr PHARMA (NASDAQ:ATYR) last posted its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.05. Equities analysts predict that Atyr PHARMA INC will post -0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Atyr PHARMA

A number of hedge funds and other institutional investors have recently modified their holdings of ATYR. JPMorgan Chase & Co. lifted its stake in shares of Atyr PHARMA by 52.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after acquiring an additional 10,754 shares during the last quarter. Kingswood Wealth Advisors LLC bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at about $170,000. Alterna Wealth Management Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at about $36,000. D.A. Davidson & CO. bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at about $141,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at about $144,000. Institutional investors own 61.72% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ATYR. Leerink Partnrs upgraded Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Leerink Partners began coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 target price for the company. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a research report on Friday, March 14th. Finally, Cantor Fitzgerald started coverage on Atyr PHARMA in a research report on Monday, January 6th. They set an “overweight” rating for the company. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $18.60.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.